NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) has responded to solicitations from the US Department of Defense (DoD) requesting development projects for live Listeria vaccines. The company has applied for approximately $5.0 million in grants from the DOD in the development of its live Listeria vaccines directed against HER-2 for breast cancer and HMW-MAA, an antiangiogenic vaccine.
